HubsFTC Issues Revised Guidance for Complying with the Health Breach Notification Rule
Client UpdatesLitigation Update
Select Options
Thought Leadership
results
Page of
FTC Supports Eliminating FDA Distribution Restraints and Facilitating Entry in Healthcare Consumer Products – Hearing Aids
Client UpdatesAntitrust Update
Remedies in FTC's Vyera Case Create Strict Standard for Pharmaceutical Company Conduct
Client UpdatesAntitrust Update
Tearing Down Regulatory Barriers to Healthcare Consumer Product Distribution: FTC's Challenge in Board of Dental Examiners of Alabama Demonstrates Continued Antitrust Pressure to Push Healthcare Products Over-the-Counter
Client UpdatesAntitrust Update
A Revolution in EU Merger Control: The Implications of the European Commission’s Revised Referral Policy for Deal Makers in the Life Sciences Sector
Client UpdatesAntitrust Update
What FTC Victory Means For Reverse Payment Settlements
External ArticleLaw360
Fifth Circuit Hands FTC Win in FTC’s First Fully-Litigated Reverse-Payment Case Following the Supreme Court’s Landmark Actavis Decision
Client UpdatesAntitrust Update
How Are Consumers Being Protected in the Wake of COVID-19 Travel Cancellations: Where Do We Stand Globally?
Speeches & PresentationsPanelist, ABA Antitrust Section, Consumer Protection Committee
EMLO: EU & Maritime policy: A Review of 2020 and Preview of 2021
WebinarFTC Issues Decision in Impax, Scrutinizes Reverse Payments Under Actavis
External ArticleThe AIPLA Antitrust News, AIPLA Committee on Antitrust Law
Reverse Payments and Beyond: Antitrust Risks for Pharmaceutical and Biotechnology Companies Amid Heightened Scrutiny of Prescription Drug Pricing
External ArticleAmerican Health Lawyers Association PG Briefing
The FDA’s and FTC’s Increased Focus on Generic Drug Competition Signals Enhanced Attention to REMS Issues
External ArticleABA’s Antitrust Health Care Chronicle